Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays… Read more
Microbix Biosystems Inc. (MBXBF) - Net Assets
Latest net assets as of September 2025: $27.79 Million USD
Based on the latest financial reports, Microbix Biosystems Inc. (MBXBF) has net assets worth $27.79 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($37.41 Million) and total liabilities ($9.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.79 Million |
| % of Total Assets | 74.28% |
| Annual Growth Rate | 13.52% |
| 5-Year Change | 49.75% |
| 10-Year Change | 81.72% |
| Growth Volatility | 58.17 |
Microbix Biosystems Inc. - Net Assets Trend (2000–2025)
This chart illustrates how Microbix Biosystems Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Microbix Biosystems Inc. (2000–2025)
The table below shows the annual net assets of Microbix Biosystems Inc. from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $27.79 Million | -1.80% |
| 2024-09-30 | $28.30 Million | +14.92% |
| 2023-09-30 | $24.62 Million | -1.26% |
| 2022-09-30 | $24.94 Million | +34.40% |
| 2021-09-30 | $18.56 Million | +180.33% |
| 2020-09-30 | $6.62 Million | -37.18% |
| 2019-09-30 | $10.54 Million | +1.78% |
| 2018-09-30 | $10.35 Million | -31.77% |
| 2017-09-30 | $15.17 Million | -0.77% |
| 2016-09-30 | $15.29 Million | +11.81% |
| 2015-09-30 | $13.68 Million | +55.63% |
| 2014-09-30 | $8.79 Million | +58.38% |
| 2013-09-30 | $5.55 Million | +32.17% |
| 2012-09-30 | $4.20 Million | -14.36% |
| 2011-09-30 | $4.90 Million | -10.66% |
| 2010-09-30 | $5.49 Million | -8.50% |
| 2009-09-30 | $6.00 Million | -16.23% |
| 2008-09-30 | $7.16 Million | +210.92% |
| 2007-09-30 | $2.30 Million | +73.81% |
| 2006-09-30 | $1.32 Million | -44.33% |
| 2005-09-30 | $2.38 Million | +31.48% |
| 2004-09-30 | $1.81 Million | +23.15% |
| 2003-09-30 | $1.47 Million | +10.10% |
| 2002-09-30 | $1.33 Million | +2.42% |
| 2001-09-30 | $1.30 Million | +11.59% |
| 2000-09-30 | $1.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Microbix Biosystems Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3563704700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $63.42 Million | 228.25% |
| Total Equity | $27.79 Million | 100.00% |
Microbix Biosystems Inc. Competitors by Market Cap
The table below lists competitors of Microbix Biosystems Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SUPPLY ME CAP. LS -00002
F:IE6B
|
$23.67 Million |
|
CammSys Corp
KQ:050110
|
$23.68 Million |
|
DevvStream Holdings Inc.
OTCQB:DSTRF
|
$23.68 Million |
|
Shree Rama Multi-Tech Limited
NSE:SHREERAMA
|
$23.68 Million |
|
LQwD FinTech Corp
OTCQX:LQWDF
|
$23.67 Million |
|
Cokal Ltd
AU:CKA
|
$23.66 Million |
|
Onward Technologies Limited
NSE:ONWARDTEC
|
$23.66 Million |
|
Heubach Colorants India Limited
NSE:HEUBACHIND
|
$23.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Microbix Biosystems Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,297,428 to 27,787,542, a change of -509,886 (-1.8%).
- Net loss of 2,245,812 reduced equity.
- Share repurchases of 1,730,586 reduced equity.
- Other factors increased equity by 3,466,512.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.25 Million | -8.08% |
| Share Repurchases | $1.73 Million | -6.23% |
| Other Changes | $3.47 Million | +12.48% |
| Total Change | $- | -1.80% |
Book Value vs Market Value Analysis
This analysis compares Microbix Biosystems Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.67x to 1.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-09-30 | $0.18 | $0.30 | x |
| 2018-09-30 | $0.11 | $0.30 | x |
| 2019-09-30 | $0.11 | $0.30 | x |
| 2020-09-30 | $0.06 | $0.30 | x |
| 2021-09-30 | $0.15 | $0.30 | x |
| 2022-09-30 | $0.18 | $0.30 | x |
| 2023-09-30 | $0.18 | $0.30 | x |
| 2024-09-30 | $0.21 | $0.30 | x |
| 2025-09-30 | $0.20 | $0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Microbix Biosystems Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.08%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.35x
- Recent ROE (-8.08%) is below the historical average (-5.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | 0.00% | 0.67x | 1.65x | $-116.79K |
| 2001 | 11.76% | 8.06% | 1.01x | 1.44x | $22.96K |
| 2002 | 3.31% | 2.48% | 1.04x | 1.28x | $-89.36K |
| 2003 | 0.00% | 0.00% | 0.96x | 1.50x | $-146.95K |
| 2004 | 0.61% | 0.34% | 1.21x | 1.48x | $-169.88K |
| 2005 | 4.55% | 2.88% | 1.11x | 1.43x | $-129.63K |
| 2006 | 0.00% | 0.00% | 0.92x | 2.68x | $-132.47K |
| 2007 | 0.00% | 0.00% | 0.70x | 2.54x | $-230.26K |
| 2008 | 0.00% | 0.00% | 0.34x | 1.92x | $-715.92K |
| 2009 | 0.00% | 0.00% | 0.43x | 2.20x | $-599.70K |
| 2010 | 0.00% | 0.00% | 0.45x | 2.53x | $-548.73K |
| 2011 | 0.00% | 0.00% | 0.45x | 2.68x | $-490.24K |
| 2012 | 0.00% | 0.00% | 0.49x | 3.28x | $-419.83K |
| 2013 | 0.02% | 0.01% | 0.60x | 2.22x | $-553.93K |
| 2014 | 1.72% | 2.01% | 0.47x | 1.83x | $-727.92K |
| 2015 | 4.49% | 6.92% | 0.38x | 1.72x | $-753.71K |
| 2016 | 4.89% | 7.86% | 0.38x | 1.65x | $-780.77K |
| 2017 | -24.91% | -37.11% | 0.39x | 1.74x | $-5.30 Million |
| 2018 | -83.27% | -68.91% | 0.65x | 1.87x | $-9.66 Million |
| 2019 | 0.30% | 0.24% | 0.68x | 1.86x | $-1.02 Million |
| 2020 | -94.08% | -59.17% | 0.67x | 2.36x | $-6.89 Million |
| 2021 | 17.42% | 17.39% | 0.64x | 1.55x | $1.38 Million |
| 2022 | 7.17% | 9.38% | 0.58x | 1.33x | $-705.18K |
| 2023 | -0.16% | -0.24% | 0.46x | 1.45x | $-2.50 Million |
| 2024 | 12.44% | 13.86% | 0.67x | 1.35x | $690.44K |
| 2025 | -8.08% | -12.08% | 0.50x | 1.35x | $-5.02 Million |
Industry Comparison
This section compares Microbix Biosystems Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Microbix Biosystems Inc. (MBXBF) | $27.79 Million | 0.00% | 0.35x | $23.67 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |